At the news
? MIXEDIMPACT 5/10 PRESS-RELEASE filed May 12, 2026 at 07:00 ET
C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M consensus), but total revenue declined 15% YoY from $7.2M. The company highlighted clinical progress for cemsidomide and a new Roche collaboration, with a cash runway to end of 2028. The mixed earnings beat and pipeline catalysts are offset by the revenue decline.
- Q1 2026 revenue $6.152 million, down from $7.238 million YoY
- Net loss per share $-0.20, improved from $-0.37 YoY
- Beat consensus EPS ($-0.26) and revenue ($4.4M)
- Cash & equivalents $268.3 million; runway to end of 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access